Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream, a Topical JAK Inhibitor, for the Treatment of Atopic Dermatitis (AD)

The U.S. Food and Drug Administration has approved Opzelura™ cream for short-term and non-continuous chronic treatment of atopic dermatitis.

Article from Business Wire